Initiate pivotal studies for NX-5948: Nurix is evaluating NX-5948 in an ongoing Phase 1b clinical trial in adults with relapsed or refractory B-cell malignancies and expects to initiate a suite of ...
Valleant’s recently released guide aims to help individuals better understand anemia, explore treatment options, and offer nutritional and lifestyle advice to support the management of ...
Postnatal treatment approaches to hemolytic disease of the fetus and newborn vary significantly ... adding blood or blood ...
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...
Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their ...
Within a few days, I was shunted out of the hospital with some meds, and pamphlets and told by a cardiologist who looked and ...
Days ago, Ryker McCracken was busy playing, like any other 3-year-old. But now he's in the hospital with a life-threatening ...
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given an average rating of “Moderate Buy” by the ten ...
The drug was approved by the FDA in 2022 as the first medicine to treat hemolytic anemia in adults with PK deficiency. Besides this use, the company is exploring expansions into beta thalassemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback